MAIA Biotechnology Disclosed Private Funding of Approximately $695,000 in a New Financing Round
MAIA Biotechnology Secures Approximately $695,000 Through Private Placement
MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company specializing in cancer-focused targeted immunotherapies, announced a private placement set to close on May 29, 2025. The company will sell 463,332 shares of common stock at $1.50 each to accredited investors and a company director.
The move aims to raise approximately $695,000 in gross proceeds, which will primarily support the execution of Step 1 of Part C in the Phase II trial for THIO-101, as well as general working capital. Each share of common stock offered comes with a warrant to purchase an additional share at $1.71, subject to certain conditions.
The securities being sold to the company director are in line with the company's 2021 Equity Incentive Plan. The offering is happening under Section 4(a)(2) of the Securities Act of 1933 and hasn't been registered under securities laws, making it subject to specific regulations and restrictions.
The private placement is subject to customary closing conditions and may not be offered or sold in any state prior to registration or qualification under securities laws.
MAIA Biotechnology is committed to developing and commercializing potential first-in-class drugs with novel mechanisms of action, aiming to significantly improve and extend the lives of cancer patients. The company's lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
Forward-looking statements in this press release are based on estimates, assumptions, and expectations, and actual results may vary due to uncertainties and factors beyond the company's control. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
For investor inquiries, reach out to MAIA Biotechnology's Investor Relations Contact at (872) 270-3518 or [email protected].
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company developing potential first-in-class drugs with novel mechanisms of action to improve the lives of cancer patients significantly. Learn more about MAIA at www.maiabiotech.com.
- The proceeds from MAIA Biotechnology's private placement will be used for their business, primarily supporting the execution of Step 1 of Part C in the Phase II trial for THIO-101 and general working capital.
- The company's securities, including those sold to a company director, are subject to specific regulations and restrictions as they are being offered under Section 4(a)(2) of the Securities Act of 1933 and haven't been registered under securities laws.
- MAIA Biotechnology, operating in the cloud, aims to commercialize potential first-in-class drugs with novel mechanisms of action, and they invite interested investors to contact their Investor Relations for more details on their ongoing activities and investing opportunities.
